Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one?

Nosheen Fatima  
*Aga Khan University*, nosheen.fatima@aku.edu

Maseeh uz Zaman  
*Aga Khan University*, maseeh.uzzaman@aku.edu

Areeba Zaman  
*Aga Khan University*, areeba.zaman@aku.edu

Unaiza Zaman  
*Aga Khan University*, Unaiza.zaman@aku.edu

Rabia Tehseen  
*Aga Khan University*, rabia.tahseen@aku.edu

**Recommended Citation**

Fatima, N., uz Zaman, M., Zaman, A., Zaman, U., Tehseen, R., Zaman, S. (2019). Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one?. *World Journal of Nuclear Medicine*, 18(2), 154-159.

Available at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/342
Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one?

Nosheen Fatima, Maseeh Uz Zaman, Areeba Zaman, Unaiza Zaman, Rabia Tahseen, and Sidra Zaman

Department of Radiology, The Aga Khan University Hospital, Karachi, Pakistan
1Dow University of Health Sciences, Karachi, Pakistan
2Department of Medicine, Dr. Ruth Pfau Hospital, Dow University of Health Sciences, Karachi, Pakistan
3Department of Radiation Oncology, The Aga Khan University Hospital, Karachi, Pakistan

Address for correspondence: Prof. Maseeh Uz Zaman, Department of Radiology, The Aga Khan University Hospital Karachi, Pakistan. E-mail: maseeh.uzzaman@aku.edu

Abstract

The purpose of this prospective study was to determine metabolic response predictor(s) in propensity-matched patients having lymphomas who had baseline and interim 18F-fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) using strict standardized imaging and reporting protocols. This prospective study was conducted at PET/CT section of a JCI-accredited healthcare facility from April 2017 to February 2018. Patients with baseline and interim 18FDG PET/CT scans using standardized protocol were selected. Interim scans were performed not earlier than 2nd or later than 4th chemotherapy. During the study period, 97 of 112 consecutive patients with lymphomas (Hodgkin-HL: 32/97 and Non-Hodgkin-NHL: 65/97) were included in the study. Mean age of cohort was 45 ± 19 years (71% male and 29% female) having a mean body mass index (BMI) of 25.57 ± 5.54 Kg/m² having Stage I (21%), Stage II (18%), Stage III (16%), and Stage IV (45%) disease. Bulky disease was found in 14% and FDG-avid marrow deposits in 33%. Standardized PET/CT imaging protocol as per EANM guidelines was strictly adopted for baseline and interim studies. %Δ changes in fasting blood sugar, 18FDG dose, uptake time, and liver SUV mean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively. Based on Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97) and nonresponders having Score 4–5 (48/97). The demographic analysis found no significant difference between responders and nonresponders for age, gender, BMI, NHL, and advance disease (Stage III and IV) in both groups (χ²: 5.12; receiver operating characteristic [95% confidence interval]: 0.616 [0.51–0.713]; P =0.528). Among responders, baseline SUVmax and tumor size had a direct correlation with a metabolic
response on iPET, more pronounced in NHL than HL groups (SUV\textsubscript{max}: 13.4 vs. 19.5 and size: 52 vs. 87 mm; \(P < 0.0001\)). We conclude that no significant predictor was found for response in propensity-matched patients with lymphomas (both HL and NHL) who had baseline and interim PET/CTs acquired with a standardized protocol. However, NHL responders were found to have higher baseline median SUV\textsubscript{max} and larger lesion size as compared to HL responders. Although, these data are not in concordance with published findings but need to be validated with larger studies using standardized imaging and reporting protocols in propensity-matched patients with lymphomas.

**Keywords:** Interim positron-emission tomography/computed tomography, lymphoma, metabolic response, predictors, standardization

**INTRODUCTION**

In the Western world, lymphoma is the 6\textsuperscript{th} most common malignancy which accounts for 4.8% of all malignancies.[1] Lymphomas are treated with chemotherapy, immune-chemotherapy, or radiation therapy, either as monotherapy or as combined modality treatment. In current practice, \(^{18}\text{F}\)-Fluorodeoxyglucose positron-emission tomography/computed tomography (\(^{18}\text{FDG PET/CT}\)) is considered as the standard of care due to its high diagnostic accuracy in staging and response evaluation at the end of treatment (ePET).[2] Interim PET/CT (iPET) performed during chemotherapy is being widely investigated in Hodgkin's lymphoma (HL), diffuse large B-Cell lymphomas, and other subsets of non-HL (NHL) for response-adapted therapy.[3] However, results are quite variable as a negative iPET has high negative predictive value (>80%) but a positive iPET has significantly low positive predictive value (around 15%) for progression-free survival (PFS).[3] This is because iPET cannot discriminate between the presence of residual viable neoplastic tissue and a nonspecific inflammatory host response.[3,4] This heterogeneity is caused by adjustable and nonmodifiable factors seen in patient population of published studies. Adjustable factors include age and gender (significantly different age groups with gender predominance), nonstandardized imaging protocols, and interpretation criteria used in different studies. Nonmodifiable factors include tumor behavior and presence of microenvironment cells such as CD8\textsuperscript{+} tumor-infiltrating lymphocytes and PD1-positive lymphocytes.[5] Hence, it is imperative to conduct studies on patients’ population with minimal impact of above-mentioned adjustable factors.

The purpose of this study was to determine metabolic response predictor(s) in propensity-matched patients having lymphomas who had baseline and interim \(^{18}\text{FDG PET/CT}\) using a standardized imaging and interpretation protocols.

**MATERIAL AND METHODS**

This prospective study was conducted at PET/CT Section of Department of Radiology, Aga Khan University Hospital Karachi, Pakistan from July 2017 to February 2018. We included patients with biopsy-proven lymphomas which were referred for \(^{18}\text{FDG PET/CT}\) studies at baseline and midtreatment scan performed not earlier than 2\textsuperscript{nd} or later than 4\textsuperscript{th} chemotherapy (iPET) for response evaluation. We strictly followed a standardized protocol for \(^{18}\text{FDG PET/CT}\) as per European Association of Nuclear Medicine (EANM) guidelines for both studies.[6] Response evaluation was assessed on visual assessment using Deauville's 5-point scoring system[7] and patients with Score 1–3 were considered as responders (complete metabolic response) while those with Scores 4 and 5 as nonresponders (partial metabolic response).

\textsuperscript{18}\text{Fluorodeoxyglucose positron-emission tomography/computed tomography imaging
FDG PET/CT was performed as per the institutional protocol adopted from EANM guidelines. All patients had 4–6 h fasting (only plain water was allowed) and a fasting blood sugar <200 mg% before receiving an intravenous 18F FDG dose of 3 MBq/Kg in the uptake room. During uptake period, (55–75 min) patients were requested to lie comfortably and allowed to take about 500–1000 ml of plain water. Bladder was emptied before call the patient for PET/CT imaging suite equipped with Celesteion, Toshiba, Japan. A low-dose CT examination (midbrain to midthigh) from head to toe followed by acquisition of PET imaging using 3 min/bed position from toe to head in all patients. Follow-up scans were performed with the same protocols, keeping 18F FDG dose, uptake time, and hepatic SUV mean of baseline and follow-up studies within ±10%, ±15%, and 20% minutes, respectively, as per published recommendations. Nodal mass ≥10 cm was considered as a bulky disease and splenomegaly when ≥13 cm. SUV\textsubscript{max} were measured over the hottest tumor deposits in both scans and % change in the highest SUV\textsubscript{max} of baseline and iPET studies (%\(\Delta\)SUV\textsubscript{max}) were also measured. Similarly, % change in size of the largest lesion (%\(\Delta\) size) in baseline and iPET scans were also measured.

**Statistical analysis**

Comparisons between patient groups were performed using Student's \(t\)-test for continuous variables and the Chi-square test for categorical variables. Continuous variables were described by mean ± standard deviation. Multiple regression analysis was performed to calculate the area under the curve and odd ratios for age, gender, body mass index (BMI), baseline SUV\textsubscript{max}, bulky disease, and baseline lesion size in lymphoma responders. Kaplan–Meier cumulative response for HL and NHL responders was performed, and curves were compared using the log-rank test. The median response for age, BMI, baseline SUV\textsubscript{max}, and baseline largest lesion size was expressed with a corresponding 95% of confidence interval [CI]. Statistical significance was defined as a value of \(P < 0.05\). Commercially, available packages Microsoft excel 2010, Medcalc, and statistical package for social sciences (SPSS 19 (IBM Company, SPSS, Inc, USA)) were used.

**RESULTS**

During the study period, 97 of 112 consecutive patients (15 patients who did not have iPET were excluded) with lymphomas. Thirty-two patients (32/97) had HL while 65/97 had NHL. Mean age of total cohort was 45 ± 19 years (71% male and 29% female) having a mean BMI of 25.57 ± 5.54 Kg/m\(^2\) [Table 1]. Patients were categorized to have Stage I (21%), Stage II (18%), Stage III (16%), and Stage IV (45%) disease [Table 2]. Bulky disease was found in 14%, splenic involvement in 30%, hepatic in 09%, extralymphatic in 37%, and 33% had 18FDG-avid marrow deposits [Table 2]. Pulmonary nodules (both 18FDG avid and nonavid) were seen in 29% while pleural effusion and ascites were seen in 9% and 4%, respectively [Table 2]. %\(\Delta\) changes in fasting blood sugar, 18FDG dose, uptake time, and liver SUVmean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively [Table 1]. Based on Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97); [Figure 1] and nonresponders having Score 4 and 5 (48/97; [Figure 2 and Table 1]. Demographic analysis found no significant difference between responders and nonresponders for age, gender, BMI, staging, the presence of bulky disease or marrow involvement, and study protocol (baseline and iPET) [Tables 1 and 2]. No significant coefficient or odd ratios were found on multivariate analysis for age, gender, SUV\textsubscript{max}, size, BMI, NHL, and advance disease (stage III and IV) in both groups (\(\chi^2\): 5.12; receiver operating characteristic [95% CI]: 0.616 (0.51–0.713); \(P =0.528\)) [Table 3]. Among the responders, 18/49 had HL and 31/49 had NHL. HL responders were found to be significantly younger with significant fall in BMI on iPET as compared to NHL responders. Rest of the variables was found to be nonsignificant Table 4. Among the responders, median SUV\textsubscript{max} and size were significantly lower in HL as compared to NHL (SUV\textsubscript{max}: 13.4 vs. 19.5 and size: 52 vs. 87 mm; \(P < 0.0001\)) [Figures 3 and 4].
**DISCUSSION**

18FDG PET/CT has revolutionized the management of lymphomas and considered as gold standard for accurate staging and response evaluation at the end of treatment.\[10\] However, the role of interim 18FDG PET/CT (iPET) in response adaptation in lymphomas (especially in NHL) is under evaluation due to variable results observed in various trials.\[9\] The basic reason is high false-positive rate ranging from 57% \[11\] to 94% \[12\] due to 18FDG uptake by posttherapy inflammatory tissue rather than viable tumor.\[13\] Other possible reasons for variable results are heterogeneity in patients’ population (age and gender predominance), nonstandardized imaging, and interpretation criteria used in different studies. In the present study, we studied the factors predicting the metabolic response on iPET scan.

In this study, age was not found to have significant relation in responders and nonresponders which is in contradiction to published facts that age is considered as a negative predictor of response.\[14\] BMI is considered as a better predictor of response and overall survival (OS) in patients with lymphoma.\[15\] Our data did not show any impact of BMI in responders and nonresponders. This is in concordance with another published study which also failed to show the impact of BMI on metabolic response.\[16\] Response rate (Deauville score 1–3 on iPET) was >50% in HL while <50% in NHL, but these were not statistically significant which could be attributed to small sample size. However, this response rate is almost similar to a recently published study having a response rate of 53% \[12\] but significantly lower than another study having a response rate as high as 72%.\[11\] Importantly, SUV\textsubscript{max} and size of the largest lesion on baseline PET/CT did not show any significant difference between responders and nonresponders on iPET. Our findings are in concordance with another published study which did not find any significant correlation of baseline SUV\textsubscript{max} with response on iPET.\[17\] Univariate and multivariate analyses also failed to show any significant impact of age, gender, BMI, baseline SUV\textsubscript{max} and lesion size, NHL, and advance disease on the metabolic response on iPET. These observations are surprising as most of the published studies did find the impact of these factors on PFS. However, we have investigated the impact of these factors on the metabolic response on iPET and not PFS or OS as data are being collected in studied cohort until writing this manuscript. We feel that large sample size studies with propensity-matched patients having 18FDG PET/CTs with standardized imaging and reporting protocols are deemed necessary to further explore this observation.

We did not observe any significant difference of staging, extranodal involvement, bulky disease, and marrow involvement between responders and nonresponders. These observations are in contradiction to published findings revealing the poor impact of bulky disease, staging, and extranodal involvement on PFS.\[14\] HL responders were found to be significantly younger with a higher decline in BMI as compared to NHL responders. This could be secondary to wider range of BMI at baseline in HL patients. This was also confirmed by no statistically significant difference on cumulative response by median BMI in both HL and NHL groups (\(P = 0.546\)).

Another important observation in our study is that baseline SUV\textsubscript{max} and tumor size among total cohort (more pronounced in NHL than HL) had a direct correlation with a metabolic response on iPET. This is in contradiction to the study by Mikhaeel et al.\[18\] revealing negative impact of SUV\textsubscript{max} and metabolically active tumor burden on PFS. However, in current study, we have studied the impact of metabolic response on iPET and we need longer follow-up to validate these findings for PFS.

Our study has some limitations which need to be addressed in the future studies. First, the sample size is small which was due to strict inclusion criteria. We did not include those patients who had baseline PET/CT performed outside for the sake of maintaining standardization. Second, we did not validate nonresponders on iPET by biopsy to ascertain false-positive results. Third, we did not subgroup HL and...
NHL responders to see the response in early and advanced disease as it would further attenuate the sample size. Fourth, end point of our study is metabolic response on iPET rather than PFS which needs follow-up which is currently underway.

**CONCLUSION**

We conclude that no significant predictor was found for response in propensity-matched patients with lymphomas (both HL and NHL) who had baseline and interim PET/CT acquired with a standardized protocol. However, NHL responders were found to have higher baseline median SUV$_\text{max}$ and larger lesion size as compared to HL responders. Although, these data are not in concordance with published findings but need to be validated with larger studies using standardized imaging and reporting protocols in propensity-matched patients with lymphomas.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. [PubMed: 28055103]

2. Kobe C, Dietlein M, Hellwig D. PET/CT for lymphoma post-therapy response assessment in Hodgkin lymphoma and diffuse large B-cell lymphoma. Semin Nucl Med. 2018;48:28–36. [PubMed: 29195615]

3. Gallamini A, Zwarthoed C. Interim FDG-PET imaging in lymphoma. Semin Nucl Med. 2018;48:17–27. [PubMed: 29195613]

4. Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med. 2012;42:267–80. [PubMed: 22681676]

5. Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954–61. [PubMed: 27251642]

6. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. [PMCID: PMC4315529] [PubMed: 25452219]

7. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50:1257–60. [PubMed: 19544140]

8. Boellaard R. Need for standardization of 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52(Suppl 2):93S–100S. [PubMed: 22144561]

9. Cheson BD. PET/CT in lymphoma: Current overview and future directions. Semin Nucl Med. 2018;48:76–81. [PubMed: 29195620]

10. Barrington SF, Mikhail NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.
11. Cox MC, Ambrogi V, Lanni V, Cavalieri E, Pelliccia S, Scopinaro F, et al. Use of interim [18F] fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. Leuk Lymphoma. 2012;53:263–9. [PubMed: 21846184]

12. Lazarovici J, Terroir M, Arfi-Rouche J, Michot JM, Mussot S, Florea V, et al. Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2017;44:2018–24. [PubMed: 28634685]

13. Adams HJA, Kwee TC. Interim FDG-PET in lymphoma, a questionable practice in hematology. Eur J Nucl Med Mol Imaging. 2017;44:2014–7. [PubMed: 28761975]

14. Shi Z, Ding H, Shen QW, Lu XG, Chen JY, Chen X, et al. The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL): Strobe compliant. Medicine (Baltimore) 2018;97:e9583. [PMCID: PMC5943112] [PubMed: 29505542]

15. Weiss L, Melchhardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 2014;25:171–6. [PubMed: 24299961]

16. Li T, Liu ZG, Liang PQ, Wang HT. Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China. Leuk Lymphoma. 2017;58:1624–9. [PubMed: 27868453]

17. Park S, Moon SH, Park LC, Hwang DW, Ji JH, Maeng CH, et al. The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. Am J Hematol. 2012;87:937–40. [PubMed: 22730093]

18. Mikhaeel NG, Smith D, Dunn JT, Phillips M, Møller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209–19. [PMCID: PMC4865540] [PubMed: 26902371]
## Table 1

Patients’ demographics in Hodgkin and Non-Hodgkin lymphomas labeled as a responder and nonresponder on interim \(^{18}\)fluorodeoxyglucose positron-emission tomography/computed tomography study

| Variables                              | Total (n=97) | Responder (n=49) | Non-responder (n=48) | Test values | P    |
|----------------------------------------|--------------|------------------|----------------------|-------------|------|
| Age mean±SD (range)                    | 45±19 (06-77) years | 42±18 (06-77) years | 47±19 (08-77) years | 1.331 | 0.187|
| Gender (male:female)                   | 69:28 (71%:29%) | 32:17 (65%:35%) | 37:11 (77%:23%) | 1.676 | 0.195|
| BMI (kg/m\(^2\)) (mean±SD)            | 25.57±5.54 | 26.18±5.58 | 24.95±5.48 | −1.095 | 0.276|
| %Δ BMI (mean±SD)                       | 0.44%±7.44% | 0.81%±7.09% | 0.07%±7.83% | −0.488 | 0.627|
| %Δ FBS (mean±SD)                       | 3.96%±23.75% | 6.83%±28.76% | 1.91%±21.42% | −0.954 | 0.343|
| %Δ FDG dose (mean±SD)                  | 2.83%±27.61% | 0.04%±34.11% | 5.76%±18.73% | 1.021 | 0.310|
| %Δ Uptake period (mean±SD)             | 2.49%±20.55% | 1.38%±18.78% | 3.63%±22.35% | 0.537 | 0.592|
| %Δ Mean hepatic uptake (mean±SD)       | 12.15%±34.60% | 16.52%±34.94% | 7.95±34.10 | −1.222 | 0.225|
| %Δ CTDI (mean±SD)                      | 9.77%±24.32% | 10.90%±26.18% | 8.61±22.47 | −0.462 | 0.645|
| %Δ DLP (mean±SD)                       | 8.59%±23.24% | 7.51%±23.54% | 9.68%±23.14% | 0.458 | 0.648|
| Hodgkin lymphoma (%)                   | 32 (33) | 18 (56) | 14 (44) | 1.382 | 0.239|
| Non-Hodgkin lymphoma (%)               | 65 (67) | 31 (48) | 34 (52) | 0.154 | 0.695|
| Highest SUV (mean±SD)                  | 13.7±8.3 | 14.0±8.25 | 13.29±8.49 | −0.418 | 0.677|
| Largest lesion (mm), (mean±SD)         | 58±47 | 62±49 | 55±46 | −0.725 | 0.470|
| %Δ in highest SUV\(_{\text{max}}\) (mean±SD) | 58%±41% | 81%±21% | 34%±41% | −7.127 | <0.0001*|
| %Δ lesion size, Mean±SD                | 58%±42% | 68%±24% | 47%±53% | −2.522 | 0.0133*|

*P<0.05. BMI: Body mass index; SD: Standard deviation; FBS: Fasting blood sugar; CTDI: Computed tomography dose index; DLP: Dose-length product; SUV\(_{\text{max}}\): Maximum standardized uptake value; FDG: Fluorodeoxyglucose
### Table 2

Tumor demographics

| Variables                  | Total (n=97), n (%) | Responder (n=49), n (%) | Nonresponder (n=48), n (%) | Test values | P     |
|----------------------------|---------------------|-------------------------|---------------------------|-------------|-------|
| Stage I                    | 20 (21)             | 11 (22)                 | 9 (19)                    | 0.132       | 0.716 |
| Stage II                   | 17 (18)             | 8 (16)                  | 9 (19)                    | 0.150       | 0.699 |
| Stage III                  | 16 (16)             | 8 (16)                  | 8 (17)                    | 0.017       | 0.895 |
| Stage IV                   | 44 (45)             | 22 (45)                 | 22 (45)                   | 0.000       | 1.000 |
| Spleen involvement         | 29 (30)             | 13 (27)                 | 16 (33)                   | 0.412       | 0.521 |
| Liver involvement          | 9 (9)               | 3 (6)                   | 6 (12)                    | 1.058       | 0.304 |
| Bulky disease ≥100 mm      | 14 (14)             | 7 (14)                  | 7 (15)                    | 0.019       | 0.889 |
| Marrow involvement         | 32 (33)             | 16 (33)                 | 16 (33)                   | 0.000       | 1.000 |
| Extra lymphoid organ       | 36 (37)             | 17 (35)                 | 19 (40)                   | 0.256       | 0.613 |
| involvement                |                     |                         |                           |             |       |
| Lung nodules               | 28 (29)             | 15 (31)                 | 13 (27)                   | 0.186       | 0.666 |
| Pleural effusion           | 9 (09)              | 5 (10)                  | 4 (08)                    | 0.117       | 0.732 |
| Ascites                    | 4 (04)              | 2 (04)                  | 2 (04)                    | 0.000       | 1.000 |
| Incidental findings        | 25 (26)             | 10 (20)                 | 15 (31)                   | 1.531       | 0.216 |

*P<0.05
Six-year-old male with a known case of classical Hodgkin's lymphoma. $^{18}$F-fluorodeoxyglucose positron-emission tomography/computed tomography revealed Stage IV disease on baseline and complete metabolic response (score 01 on Deauville 5PS) on interim scan after receiving 4th cycle of chemotherapy.
Figure 2

Twenty-three-year-old male with a known case of classical Hodgkin's lymphoma, $^{18}$fluorodeoxyglucose positron-emission tomography/computed tomography revealed Stage IV disease on baseline and partial metabolic response (score 05 on Deauville 5PS) on interim scan after receiving 2nd cycle of chemotherapy.
Table 3
Lymphoma response on interim $^{18}$fluorodeoxyglucose positron-emission tomography/computed tomography in correlation with age, baseline maximum standardized uptake value, baseline largest lesion, and baseline body mass index

| Lymphoma response versus variables | Logistic regression $\chi^2$ | Area under the ROC Curve (95% CI) | P  |
|-----------------------------------|-------------------------------|-----------------------------------|----|
| Age + gender + SUV$_{\text{max}}$ + size + BMI + NHL + advanced disease | 5.122                         | 0.616 (0.512-0.713)              | 0.528 |

| Lymphoma response versus variables | Coefficient (SE) | OR (95% CI) | P  |
|-----------------------------------|------------------|-------------|----|
| Age (years)                       | $-0.015$ (0.014) | 0.985 (0.958-1.012) | 0.270 |
| Male gender                       | $-0.504$ (0.472) | 0.604 (0.239-1.523) | 0.286 |
| Baseline SUV$_{\text{max}}$       | 0.008 (0.028)    | 1.008 (0.954-1.065) | 0.781 |
| Baseline largest lesion (mm)      | 0.008 (0.05)     | 1.003 (0.993-1.013) | 0.590 |
| Baseline BMI (kg/m$^2$)           | 0.054 (0.040)    | 1.056 (0.975-1.144) | 0.183 |
| NHL                               | $-0.135$ (0.543) | 0.873 (0.301-2.532) | 0.803 |
| Advance disease (Stage III, IV and Bulky disease) | 0.064 (0.048)    | 1.066 (0.413-2.751) | 0.895 |

*P*<0.05. SUV$_{\text{max}}$: Maximum standardized uptake value; BMI: Body mass index; CI: Confidence interval; SE: Standard error; NHL: Non-Hodgkin lymphoma
### Table 4

Demographic comparisons in Hodgkin and non-Hodgkin lymphomas labeled as responders on interim $^{18}$F-fluorodeoxyglucose positron-emission tomography/computed tomography study

| Variables                                      | Responders ($n=49$) | HL ($n=18$) | NHL ($n=31$) | Test values | $P$ |
|------------------------------------------------|---------------------|-------------|--------------|-------------|-----|
| Age mean±SD (range)                            | 42±18 (06-77) years | 30±17 (06-77) years | 52±15 (21-77) years | 4.713 | <0.0001* |
| Gender (male:female)                           | 32:17 (65%:35%)     | 11:07 (61%:39%) | 21:10 (68%:32%) | 1.676 | 0.195 |
| BMI (kg/m$^2$), (mean±SD)                      | 26.18±5.58%         | 24.38±7.33% | 26.15±4.35% | 1.064 | 0.293 |
| %Δ BMI, (mean±SD)                              | 0.81±7.09%          | −3.42±5.67% | 1.02±7.69%  | 2.076 | 0.043* |
| %Δ FBS, (mean±SD)                              | 6.83±28.76%         | −0.54±15.00%| 5.64±26.34% | −0.911 | 0.367 |
| %Δ FDG dose, (mean±SD)                         | −1.00±15.00%        | 1.13±21.0%  | 3.67±30.53% | 0.312 | 0.756 |
| %Δ Uptake period, (mean±SD)                    | 1.38±18.78%         | 0.62±20.93% | −4.03±20.34%| −0.763 | 0.449 |
| %Δ Mean hepatic uptake, (mean±SD)              | 16.52±34.94%        | −9.25±23.80%| −3.58±38.93%| 0.585 | 0.561 |
| %Δ CT-DI, (mean±SD)                            | 10.90±26.18%        | −12.5±24.28%| −8.41±24.41 | 0.567 | 0.574 |
| %Δ DLP (mean±SD)                               | 7.51±23.54%         | −10.56%     | −7.62±22.58%| 0.424 | 0.674 |
| Highest SUV$\text{max}$, mean±SD (range)       | 14.0±8.3 (1.5-38)   | 10.9±4.4 (3.2-21.3) | 15.0±9.5 (1.5-38) | 1.721 | 0.091 |
| Largest lesion (mm), mean±SD (range)           | 62±49 (12-266)      | 45±28 (12-95)  | 53±46 (14-266) | 0.668 | 0.507 |
| %Δ in highest SUV$\text{max}$, Mean±SD (range) | 81%±21% (+26% + 95%) | 68%±25% (44%-94%) | 52%±46% (07%-95%) | −1.360 | 0.180 |
| %Δ lesion size, Mean±SD (range)                | 68%±24% (00%-97%)   | 62%±28% (33%-92%) | 55%±48% (00-97%) | −0.564 | 0.575 |

*P*<0.05. SD: Standard deviation; BMI: Body mass index; FBS: Fasting blood sugar; CT-DI: Computed tomography dose index; DLP: Dose-length product; SUV$\text{max}$: Maximum standardized uptake value; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma.
Figure 3

Kaplan–Meier plot for cumulative response on first interim positron-emission tomography/computed tomography in Hodgkin and non-Hodgkin lymphomas against the highest median baseline maximum standardized uptake value. HL = Hodgkin lymphoma, NHL = Non-Hodgkin lymphoma
Figure 4

Kaplan–Meier plot for cumulative response on first interim positron–emission tomography/computed tomography in Hodgkin and non-Hodgkin lymphomas against median baseline lesion size in the largest dimension. HL = Hodgkin lymphoma, NHL = Non-Hodgkin lymphoma

Articles from World Journal of Nuclear Medicine are provided here courtesy of Wolters Kluwer -- Medknow

Publications